Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Neuropsychopharmacol. 2012 Aug;15(7):1003-14. doi: 10.1017/S1461145711001738. Epub 2012 Jan 5.

Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?

Author information

1
Janssen Scientific Affairs, LLC, Titusville, NJ, USA. lalphs@its.jnj.com

Abstract

The effect of placebo observed in schizophrenia clinical trials represents a growing problem that interferes with signal detection for treatments, increases costs of development, discourages investment in schizophrenia research and delays the introduction of new treatments. This paper seeks to clarify key issues related to this problem and identify potential solutions to them. Differences between placebo effect and response are characterized. Recent insights into the central nervous system mechanisms of placebo effect are described. This is followed by a description of protocol/study design and study conduct issues that are contributing to a growing placebo effect in clinical trials. Potential solutions to these problems are provided.

PMID:
22217384
PMCID:
PMC3405769
DOI:
10.1017/S1461145711001738
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Cambridge University Press Icon for PubMed Central
    Loading ...
    Support Center